Department of Chemistry, Faculty of Science, Karaj Branch, Islamic Azad University, Karaj, Iran.
Neurophysiology Research Center, Shahed University, Tehran, Iran.
Mini Rev Med Chem. 2019;19(1):72-78. doi: 10.2174/1389557518666180716122608.
Currently, there is no conclusive cure for Alzheimer's disease (AD) and existing treatments mainly offer symptomatic relief. Dysfunction of the cholinergic system plays an important role in the pathogenesis of AD. Tacrine (1, 2, 3, 4-tetrahydroacridin-9-amine, III) was the first approved agent for the palliative therapy of AD but its use is associated with some complications. Development of novel multi target derivatives of Tacrine with lower complications is strongly warranted. In this study, new aminobenzothiazole (1-5, with many useful biological and pharmacological properties) analogues (IV-VIII) were synthesized by changing of amine moiety of III. Then, the effects of these new compounds on learning and memory impairment in scopolamine-induced model of amnesia were studied and the outcomes were compared with control and Tacrine groups in rat.
The rats received Tacrine or its derivatives (IV-VIII) i.p. for two weeks at a dose of 10 mg/kg. For induction of amnesia, scopolamine at a dose of 1 mg/kg was daily administered i.p. started on day-8 till the end of the study. Behavioral experiments including Y-maze, novel object recognition (discrimination) and passive avoidance paradigms were conducted at week 2.
Data analysis showed that some Tacrine derivatives, especially VII with 2-amino, 6-nitrobenzothiazole moiety, could markedly and significantly improve alternation score, discrimination ratio and step through latency compared to control and Tacrine groups.
These findings indicated that some of these derivatives (especially compounds VI and VII) are capable to mitigate learning and memory deficits in scopolamine-induced model of amnesia in rats and may have potential benefit in management of patients with AD.
目前,阿尔茨海默病(AD)尚无确切的治愈方法,现有的治疗方法主要提供症状缓解。胆碱能系统功能障碍在 AD 的发病机制中起着重要作用。他克林(1,2,3,4-四氢吖啶-9-胺,III)是第一种被批准用于 AD 姑息治疗的药物,但它的使用与一些并发症有关。强烈需要开发具有较低并发症的新型他克林多靶点衍生物。在这项研究中,通过改变 III 的胺部分,合成了新的氨基苯并噻唑(1-5,具有许多有用的生物学和药理学特性)类似物(IV-VIII)。然后,研究了这些新化合物对东莨菪碱诱导的遗忘模型中学习和记忆障碍的影响,并将结果与对照组和他克林组进行了比较。
大鼠腹腔注射他克林或其衍生物(IV-VIII)两周,剂量为 10mg/kg。为了诱导健忘症,每天腹腔注射东莨菪碱 1mg/kg,从第 8 天开始,持续到研究结束。在第 2 周进行 Y 迷宫、新物体识别(辨别)和被动回避范式等行为实验。
数据分析表明,一些他克林衍生物,特别是具有 2-氨基、6-硝基苯并噻唑部分的 VII,与对照组和他克林组相比,可显著改善交替评分、辨别率和步出潜伏期。
这些发现表明,这些衍生物中的一些(特别是化合物 VI 和 VII)能够减轻东莨菪碱诱导的遗忘模型中大鼠的学习和记忆缺陷,并且可能对 AD 患者的管理有潜在益处。